Suppr超能文献

检测脑脊液神经丝轻链作为α-突触核蛋白病的标志物

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies.

作者信息

Canaslan Sezgi, Schmitz Matthias, Villar-Piqué Anna, Maass Fabian, Gmitterová Karin, Varges Daniela, Lingor Paul, Llorens Franc, Hermann Peter, Zerr Inga

机构信息

Department of Neurology, University Medical Center Göttingen and the German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.

Network Center for Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Madrid, Spain.

出版信息

Front Aging Neurosci. 2021 Sep 22;13:717930. doi: 10.3389/fnagi.2021.717930. eCollection 2021.

Abstract

Alpha-synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are a class of neurodegenerative diseases. A diagnosis may be challenging because clinical symptoms partially overlap, and there is currently no reliable diagnostic test available. Therefore, we aimed to identify a suitable marker protein in cerebrospinal fluid (CSF) to distinguish either between different types of alpha-synucleinopathies or between alpha-synucleinopathies and controls. In this study, the regulation of different marker protein candidates, such as alpha-synuclein (a-Syn), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (tau) in different types of alpha-synucleinopathies, had been analyzed by using an ultrasensitive test system called single-molecule array (SIMOA). Interestingly, we observed that CSF-NfL was significantly elevated in patients with DLB and MSA compared to patients with PD or control donors. To differentiate between groups, receiver operating characteristic (ROC) curve analysis resulted in a very good diagnostic accuracy as indicated by the area under the curve (AUC) values of 0.87-0.92 for CSF-NfL. Furthermore, we observed that GFAP and tau were slightly increased either in DLB or MSA, while a-Syn levels remained unregulated. Our study suggests NfL as a promising marker to discriminate between different types of alpha-synucleinopathies or between DLB/MSA and controls.

摘要

α-突触核蛋白病,如帕金森病(PD)、路易体痴呆(DLB)和多系统萎缩(MSA),是一类神经退行性疾病。由于临床症状部分重叠,且目前没有可靠的诊断测试,因此诊断可能具有挑战性。因此,我们旨在确定脑脊液(CSF)中一种合适的标记蛋白,以区分不同类型的α-突触核蛋白病,或区分α-突触核蛋白病与对照。在本研究中,我们使用一种名为单分子阵列(SIMOA)的超灵敏检测系统,分析了不同类型α-突触核蛋白病中不同标记蛋白候选物的调节情况,如α-突触核蛋白(a-Syn)、神经丝轻链(NfL)、胶质纤维酸性蛋白(GFAP)和总tau蛋白(tau)。有趣的是,我们观察到与PD患者或对照供体相比,DLB和MSA患者的脑脊液NfL显著升高。为了区分不同组,通过受试者工作特征(ROC)曲线分析,脑脊液NfL的曲线下面积(AUC)值为0.87-0.92,显示出非常好的诊断准确性。此外,我们观察到GFAP和tau在DLB或MSA中略有升高,而a-Syn水平保持不变。我们的研究表明,NfL是区分不同类型α-突触核蛋白病或区分DLB/MSA与对照的一个有前景的标记物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0118/8493247/0762132f1687/fnagi-13-717930-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验